CES 2023: OMRON Healthcare Introducing Initiatives to Advance Its Vision of “Going for Zero” — Elimination of Heart Attack and Stroke
KYOTO, Japan, Dec. 16, 2022 /PRNewswire/ -- OMRON Healthcare Co., Ltd. (hereinafter the Company) will exhibit at CES 2023 (*), the world's largest consumer tech show taking place in Las Vegas from Thursday, January 5, through Sunday, January 8. At the show, the Company will showcase the innovative medical devices and digital services that have been introduced over...
Novavax Announces Pricing of $65 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of...
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes
GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the "notes"). The notes are...
Digital Mental Health Company, ThoughtFull, Partners with FWD to Provide Science-Backed and Technology-Enabled Mental Health Solutions for Customers in Hong Kong and Thailand
SINGAPORE, Dec. 16, 2022 /PRNewswire/ -- Asia's leading digital mental health company, ThoughtFull, continues to bring greater accessibility of its mental wellness solutions to corporate and consumer clients across the Asia region. Today, the firm announces that it is partnering with the FWD Group Holdings Limited ("FWD Group") to launch the Mind...
Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer
HANGZHOU, China, Dec. 16, 2022 /PRNewswire/ -- Hangzhou, Zhejiang, China, , Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA),...
WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department’s Unverified List
SHANGHAI, Dec. 16, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective Dec. 16, 2022. Consequently, both subsidiaries WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co.,...
Jacobio’s KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE
BEIJING, SHANGHAI and BOSTON, Dec. 16, 2022 /PRNewswire/ -- Jacobio Pharma (1167. HK) announced that the Company's in-house KRAS G12C inhibitor JAB-21822 was granted breakthrough therapy designations for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation by the Center for Drug Evaluation (CDE)...
VISTA Eye Specialists Opens its 13th Outlet in Johor Bahru with Overwhelming Success
PETALING JAYA, Malaysia, Dec. 16, 2022 /PRNewswire/ -- VISTA Eye Specialist (VISTA) opened its 2nd outlet in Johor Bahru (JB) in November with dazzling success, bringing its total outlets in Malaysia to 13, and embarking on its journey to make available world-class eye specialist care to more Johorians. Located at the western side of Malaysia's most southern city and bordering...
EmeTerm Enters Walmart and Best Buy with New Technology
VANCOUVER, BC, Dec. 16, 2022 /PRNewswire/ -- EmeTerm, the anti-nausea wristband developed by WAT Medical Enterprise, Ltd., received its FDA clearance in 2018 as a medical device that manages nausea-induced vomiting. In December 2022, EmeTerm expanded into the retail market by introducing their new product - EmeTerm Explore in Walmart and Best Buy Canada. With outdoor activities becoming more common than ever since the COVID-19 pandemic,...
Bioved Pharmaceuticals, Inc. announces the results of its Phase III Randomized Clinical Trial in Moderate Covid-19 with Artovid-20®, a natural plant-based oral product
SAN JOSE, Calif., Dec. 16, 2022 /PRNewswire/ -- Published Nov 25, 2022 in the highly respected peer-reviewed journal Phytotherapy Research, results show statistically significant reduction in duration of illness and severity scores of the symptoms associated with Covid-19. In addition, statistical significance was seen in alleviation of symptoms such as taste and smell from Day 5. Most importantly,...
